OMEROS CORP Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- OMEROS CORP payments for repurchase of common stock for the quarter ending 2026-06-30 was $5.73M.
- OMEROS CORP payments for repurchase of common stock for the quarter ending 2026-03-31 was $4.15M.
- OMEROS CORP payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- OMEROS CORP payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00.
- OMEROS CORP payments for repurchase of common stock for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- OMEROS CORP payments for repurchase of common stock for fiscal 2024 was $11.85M, a 154.64% increase from fiscal 2023.
- OMEROS CORP payments for repurchase of common stock for fiscal 2023 was $4.65M.
- OMEROS CORP payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $5.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $9.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $4.15M 10-Q · filed 2026-05-13 | $4.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $11.85M 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $16.50M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $16.50M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | $11.85M 10-Q · filed 2025-05-15 | $16.50M derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.65M 10-K · filed 2026-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $0.00 10-K · filed 2025-03-31 | |
| 2021-12-31 | $0.00 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |